Crinetics Pharmaceuticals stock is coming off a very strong run, with the price up about 403.6% over the past three years, while the valuation checks now point to a company that screens as overvalued on market multiples and only scores as mixed overall.

• A roughly 403.6% return over three years puts Crinetics Pharmaceuticals among the stronger performers, which raises the bar for what the current price already assumes about the future.
• The agreed acquisition by Vertex Pharmaceuticals can support the current valuation, while execution risk around integrating Crinetics and its pipeline may still matter for how investors think about pricing.
• The stock passes 3 of 6 valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation on the broader tests, and you can see the breakdown in 3/6 checks here.

The issue now is whether the recent share price strength in Crinetics Pharmaceuticals already fully reflects what investors are likely to receive if and when the Vertex deal closes.

Is Crinetics Pharmaceuticals Getting Expensive on Book Value?

P/B is often useful for a research stage biotech like Crinetics Pharmaceuticals because the balance sheet, especially the cash it holds, can matter more than current earnings.

Crinetics Pharmaceuticals currently trades on a P/B of about 7.5x, which is well above the Pharmaceuticals industry average of roughly 2.6x. It also sits far below the reported peer group average of about 73.7x, which indicates that some peers trade on very high book value multiples. However, the key comparison for many investors is usually the industry baseline.

On that simpler lens, Crinetics appears expensive on P/B, since investors are paying a higher price for each dollar of net assets than is typical for the sector. The agreed US$10.0b takeover by Vertex Pharmaceuticals helps explain why the market is comfortable with a premium to book, although it still means the stock is priced well above the industry norm on this metric alone.

Overall, Crinetics Pharmaceuticals currently trades on a higher P/B multiple than the wider Pharmaceuticals industry.

The Crinetics Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Crinetics Pharmaceuticals pick up where the valuation puzzle leaves off and set out what kind of growth, margins and earnings the market could be assuming at today’s price. Each one ties a fair value estimate to a specific storyline about Crinetics Pharmaceuticals' potential catalysts and key risks, so you can track over time which version of events appears to be playing out on the Community page.

One of the top community narratives on Crinetics Pharmaceuticals: roughly fairly valued

"Recent research on Crinetics Pharmaceuticals points to a clear shift in focus toward the US$85 per share cash offer from Vertex Pharmaceuticals as the key reference point for valuation..."

Do you think there's more to the story for Crinetics Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Crinetics Pharmaceuticals now screens as overvalued on market multiples, and the recent share price move has lifted expectations to a demanding level. The mixed valuation checks suggest the stock is no longer obviously cheap, even if some metrics still sit in a reasonable range. For many investors, the key question is whether the agreed Vertex Pharmaceuticals offer fully captures the risk and reward from here, including integration and pipeline execution. That assumption, about how confidently you view the deal closing and post-deal delivery, is what really separates the bullish and cautious camps on Crinetics today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.